

E6 Stimulation
% IFNγ+ of CD8
35
30
12
9
6
3
0
No Tx
sol CpG1826
aCpG1826
sol CpG7909
aCpG7909
pIC

FIG. 1



E7 Stimulation
% IFNγ+ of CD8
60
40
20
0
No Tx
sol CpG1826
aCpG1826
sol CpG7909
aCpG7909
pIC

FIG. 2



Tetramer #1
% Tetramer+ CD8 cells
80
60
40
20
0
No Tx
sol CpG1826
aCpG1826
sol CpG7909
aCpG7909
pIC

FIG. 3



surface area (mm2)
days post dose 1
E6/E7 + aCpG
aCpG
No Tx
Percent survival
Days
E6/E7 + aCpG
aCpG
No Tx

FIG. 4



Tetramer over time (weekly)
% Tetramer+ CD8 cells
Day
E7+aCpG (1w)
E7+CpG (1w)
No Tx

FIG. 5



Tetramer overtime(aCpG)
% Tetramer+ CD8 cells
100
80
60
40
20
0
0
10
20
30
40
Day
E7+aCpG (s.d)
E7+aCpG (1w)
E7+aCpG (2w)
No Tx

FIG. 6



Tumor Size (mm2)
Size (mm2)
100
80
60
40
20
0
10
20
30
40
Days
E7+aCpG weekly
E7 + aCpG bi-weekly
E7+aCpG single dose
E7+CpG weekly
E7+CpG bi-weekly
E7+CpG single dose
no Tx

FIG. 7




Survival
Percent survival
100
50
0
0
20
40
60
Days
E7+aCpG (2w)
E7+CpG (2w)
No Tx

FIG. 8


Survival¶
Percentsurvival
100¶
50¶
0¶
0
20
40
60¶
Days¶
E7+aCpG (1w)
E7+aCpG (2w)¶
E7+aCpG (s.d)¶
No·Tx¶



IL12
E7+aCpG
E7+CpG
No Tx
pg/ml
Day 0
Day 7
TNFa
INFy
MCP-1
IL-10
IL-6

FIG. 9



Tetramer over time
% Tetramer+ CD8 cells
100
80
60
40
20
0
Dose 1
Dose 2
Dose 3
E7+aCpG
E7+aCpG+PD-1
E7+CpG
E7+CpG+PD-1
NoTx

FIG. 10



Tumor Size
Area (mm2)
200
150
100
50
0
10
20
30
40
50
days post dose 1
E7+aCpG
E7+aCpG+aPD-1
E7+CpG
E7+CpG+aPD-1
untreated

FIG. 11



Survival
Percent survival
100
50
0
0
50
100
Days post Inocculation
aCpG
aCpG + aPD1
CpG
CpG + aPD1
untreated

FIG. 12



Tetramer (All 6 Doses)
% Tetramer+ CD8 cells
60
40
20
0
Dose 1
Dose 2
Dose 3
Dose 4
Dose 5
Dose 6
0.1x aCpG
0.5x aCpG
1x aCpG
5x aCpG
10x aCpG
1x CpG
5x CpG
10x CpG
50x CpG
100x CpG

FIG. 13




FIG. 14